|
Video: What is a Stock Split?
|
|
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare endocrine disorders with unmet medical need. Co. is developing its wholly-owned product candidate, tildacerfont, as a non-steroidal therapy to provide improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia and polycystic ovary syndrome. According to our Spruce Biosciences stock split history records, Spruce Biosciences has had 0 splits. | |
|
Spruce Biosciences (SPRB) has 0 splits in our Spruce Biosciences stock split history database.
Looking at the Spruce Biosciences stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Spruce Biosciences shares, starting with a $10,000 purchase of SPRB, presented on a split-history-adjusted basis factoring in the complete Spruce Biosciences stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
10/12/2020 |
|
End date: |
04/19/2024 |
|
Start price/share: |
$17.25 |
|
End price/share: |
$0.70 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-95.94% |
|
Average Annual Total Return: |
-59.76% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$405.68 |
|
Years: |
3.52 |
|
|
|
|
|